Results 231 to 240 of about 21,216 (279)

A comprehensive review on analytical methods of Raltegravir

Pradeep Kumar, M. Mamatha, Nagireddy Roshitha Nagireddy Roshitha, Akhilesh Kumar, Swathi Naraparaju   +4 more
openalex   +1 more source

Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians. [PDF]

J Family Med Prim Care
Aydemir C, Al Saidi R, Choi JS, Ahmed MH, Mital D.   +4 more
europepmc   +1 more source

Antiretroviral Drugs Impact Autophagy Differently in Primary Human Astrocytes. [PDF]

Cells
Cheney L, McDermott G, Guzik H, Berman JW.   +3 more
europepmc   +1 more source

Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review. [PDF]

Front Pharmacol
Spanakis M, Alexakis K, Ioannou P.
europepmc   +1 more source

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

, 2017
U Restelli, G Rizzardini, Andrea Antinori, Adriano Lazzarin, M Bonfanti, P Bonfanti, D Croce   +6 more
openalex   +1 more source

Three novel epigenetic-modifying compounds identified as HIV latency-reversing agents in Ghana

Abana CZ, Boateng AT, Abaidoo-Myles A, Nartey PA, Bortey CB, Quansah DNK, Aboagye JO, Appiah-Opong R, Quaye O, Clark KM, Lamptey H, Shan L, Bonney EY, Kyei GB.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes

Clinical Infectious Diseases, 2020
BACKGROUND Although some integrase strand transfer inhibitors (INSTIs) promote peripheral and central adipose tissue/weight gain in HIV-infected individuals, the underlying mechanism has not been identified.
Christine Bourgeois, Guillaume Pourcher, Michael Atlan   +2 more
exaly   +2 more sources

HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma

Chemical Biology and Drug Design, 2023
Raltegravir, the first integrase inhibitor approved for the treatment of HIV infection, has been implicated as a promising potential in cancer treatment.
Dilara Akcora-Yildiz, N. Gonulkirmaz, T. Ozkan, M. Beksaç, A. Sunguroglu   +4 more
semanticscholar   +1 more source

Raltegravir

Drugs, 2008
* Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new cells.
Jamie D, Croxtall, Katherine A, Lyseng-Williamson, Caroline M, Perry   +2 more
  +5 more sources